Evidence map›Paper›PMID 37665652›Full record

ArticleJournal of neurointerventional surgery2024

Periprocedural unfractionated heparin bolus during endovascular treatment in acute ischemic stroke does more harm than good.

Johannes Wischmann, Ilias Masouris, Linus Keidel, Steffen Tiedt, Christoph G Trumm, Hanna Zimmermann, Thomas Liebig, Günter Höglinger, Lars Kellert, German Stroke Registry-Endovascular Treatment (GSR-ET) Investigators

Abstract read
In one paragraph

Article in Journal of neurointerventional surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. In search of real-world cerebroprotection: An institutional perspective and review of the literature.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Johannes WischmannDepartment of Neurology, LMU University Hospital, LMU Munich, Munich, Germany johannes.wischmann@med.uni-muenchen.de.ORCID http://orcid.org/0000-0003-0653-943X
Ilias MasourisDepartment of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
Linus KeidelDepartment of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
Steffen TiedtDepartment of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-8817-8457
Christoph G TrummInstitute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-1249-3338
Hanna ZimmermannInstitute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, Germany.
Thomas LiebigInstitute of Neuroradiology, LMU University Hospital, LMU Munich, Munich, Germany.
Günter HöglingerDepartment of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
Lars KellertDepartment of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.
German Stroke Registry-Endovascular Treatment (GSR-ET) Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnfractionated heparin (UFH) bolus is occasionally administered during endovascular treatment (EVT) to reduce thrombotic complications in acute ischemic stroke patients. However, the MR CLEAN-MED trial showed an increase in symptomatic intracranial hemorrhages (sICH) and a non-significant shift towards worse functional outcome with UFH administration. We aimed to analyze the impact of periprocedural UFH bolus in a real-world setting in anterior (ACS) and posterior circulation stroke (PCS) patients.

methodsWe analyzed data from the German Stroke Registry-Endovascular Treatment using propensity score matching. Primary outcome was the modified Rankin Scale at 3 months, and secondary outcome measures included mortality, angiographic outcomes, post-EVT National Institute of Health Stroke Scale scores and ICH at 24 hours.

resultsAmong 13,082 patients, 7948 with ACS (UFH bolus use in 15%) and 841 with PCS (UFH bolus use in 16.3%) were included in the propensity score matching analysis. Applying MR CLEAN-MED study criteria, UFH bolus was associated with worse functional outcomes (odds ratio [OR] 1.44; 95% CI 1.06-1.96). Analyzing all ACS and PCS patients, UFH bolus did not provide any net benefit. In ACS patients treated with intravenous thrombolysis (IVT), UFH bolus use was associated with worse functional outcomes (OR 2.40; 95% CI 1.34 to 5.06).

conclusionOur findings show transferability of the MR CLEAN-MED results into a real-world setting, confirming a negative effect of periprocedural UFH on functional outcome in this subgroup of patients. Considering all ACS and PCS patients, periprocedural UFH did not provide a net benefit and appears to be harmful, particularly in IVT-treated patients.

Indexed as

AnticoagulantsEndovascular ProceduresHeparinIschemic StrokeRegistriesAgedAged, 80 and overFemaleHumansMaleMiddle AgedTreatment OutcomeAnticoagulantsHeparinStrokeThrombectomyThrombolysis

Identifiers

PMID37665652
PMCPMC11287633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.